SKB BIO's ADC drug receives approval for its third indication
On October 11th, SKB BIO's antibody-drug conjugate Lukanasatuzumab (brand name: Jiatailai) received approval from the National Medical Products Administration for its third indication, to treat adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer with positive EGFR gene mutations that have progressed after treatment with epidermal growth factor receptor tyrosine kinase inhibitors
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments